The U.S. Supreme court ordered the Israeli pharmaceutical concern «Teva» to pay the British company GlaxoSmithKline $ 235 million compensation for patent infringement.
The jury in the state of Delaware recognized the «Teva» guilty of unlawful use of a patent GlaxoSmithKline in genernal version of the drug Coreg, for the treatment of heart failure.
Recall that in January of this year, «Teva» was ordered to pay $ 225 million for violating the antitrust laws of the United States.
In December 2016, the group reached an out of court agreement with the US authorities on payment of fine of 0,5 billion dollars in exchange for the termination of the case of bribing officials outside the United States.
In addition, 20 U.S. States filed an Executive lawsuit against six pharmaceutical companies, including the «Teva» on charges of a cartel collusion, which led to unnecessary overpricing of two drugs.